araag2/HINT huggingface dataset:
Clinical trial NCT00262210 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide epirubicin etoposide prednisolone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        -  Inclusion Criteria:

               1. Histologically proven NHL, and for which intensive chemotherapy is considered
                  treatment-of-choice.

               2. HBsAg-positive.

               3. No previous chemotherapy and radiotherapy.

               4. No concurrent radiotherapy. AGC ≧ 2,000/mm3, Platelet ≧ 100,000/mm3 of peripheral
                  blood.

               5. Total bilirubin ≦ 2.5 mg/dl. Alanine aminotransferase (SGPT) < 200 I.U/L

               6. Serum creatinine ≦1.5 mg/dl Blood urea nitrogen (BUN) ≦ 25 mg/dl

               7. Objectively measurable or evaluable disease

               8. Signed informed consent

          -  Exclusion Criteria:

               1. Age > 75 years, or Age < 15 years

               2. Pregnant or breast-feeding women.

               3. Patients with history of brain metastasis or CNS involvement.

               4. Child's class B or C in patients with liver cirrhosis.

               5. Impaired cardiac function with NYHA (New York Heart Association) classification ≧
                  GrII.

               6. Concurrent glucocorticoids use (for other reasons). The conventional use of
                  glucocorticoids for antiemetic purpose is also not allowed.
Clinical trial NCT00721409 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pd 0332991, letrozole, letrozole
SMILES: CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Inoperable estrogen receptor positive and HER2 negative breast cancer.

          -  Postmenopausal status.

          -  Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2
             - CCND1 amplification and/or loss of p16 as determined by the central laboratory.

          -  Acceptable bone marrow, liver and kidney function.

        Exclusion Criteria:

          -  Prior or concomitant treatment for advanced breast cancer.

          -  Other major cancer in the past 3 years.

          -  Important cardiovascular events in the past 6 months.
Clinical trial NCT00191347 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pemetrexed, gemcitabine
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        INCLUSION:

          1. Have a performance status of 0 to 2 on the ECOG performance status schedule.

          2. Patients may have had up to one prior systemic chemotherapy for metastatic disease is
             allowed. Prior adjuvant therapy is allowed if it has been more than one year since the
             end of therapy.

          3. Patients must have measurable disease as defined by RECIST criteria (Therasse et al.
             2000):

          4. Have adequate organ function including the following

        EXCLUSION:

        1. Have serious concomitant systemic disorders (eg, active infection) that, in the opinion
        of the investigator, would compromise the safety of the patient or compromise the patient's
        ability to complete the study.
Clinical trial NCT01078662 (phase 2, status: active, not recruiting)
Conditions: ovarian, breast, prostate, pancreatic, advanced tumours
ICD codes: Q50.32, E28.2, E28.8, E28.9, Q50.1, E28.39, E89.40
Drugs: olaparib
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed documented deleterious or suspected deleterious BRCA mutation. (The presence
             of a loss-of-function germline mutation in the BRCA1 and/or BRCA2 gene must be
             confirmed prior to consent according to local practice).

          -  Confirmed malignant solid tumours for which no standard treatment exists

          -  At least one lesion (measurable and/or non measurable) at baseline that can be
             accurately assessed by CT/MRI and is suitable for repeated assessment at follow up
             visits

        Exclusion Criteria:

          -  Any previous treatment with a PARP inhibitor, including olaparib

          -  Patients unable to swallow orally administered medication and patients with
             gastrointestinal disorders likely to interfere with absorption of the study medication

          -  Patients receiving any systematic chemotherapy, radiotherapy (except for palliative
             reasons) within 2 weeks from the last dose prior to study treatment (or a longer
             period depending on the defined characteristics of the agents used)
Clinical trial NCT01569516 (phase 2, status: unknown status)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Clinical diagnosis of probable AD based on DSM-IV and the NINCDS-ADRDA criteria.

          2. Male/female patient aged between 50 and 85.

          3. mild to moderate probable AD ：Middle school or above: 11 ≤MMSE ≤ 25, elementary
             school: 8 ≤ MMSE ≤ 20, illiteracy: 5 ≤ MMSE ≤ 16.

          4. CT or MRI scan excluding another structural brain disease in one year.

          5. Neurologic examination no significant abnormalities.

          6. Hachinski Ischemic Score < 4；Hamilton Depression Scale ≤10. Able to complete the test
             procedure, audio-visual and physical ability to act to complete the neuropsychological
             measure.

          7. Stable chaperone, more than 2 hours a day together with the patient or accumulated
             fewer than 14 hours per week.

          8. Informed consent of the patient (or legal representative) and of the caregiver
             agreeing to take part in the study.

        Exclusion Criteria:

          1. Proven or clinically suspected other type of dementia such as vascular dementia, Lewy
             body dementia, Parkinson's disease, frontotemporal dementia, g - Jakob disease
             (spastic pseudo-sclerosis), normal pressure hydrocephalus etc.

          2. Sudden onset of early dementia or with gait disorders, seizures and behavioral
             changes.

          3. Clinical manifestations of focal neurological signs (hemiparesis, sensory loss, visual
             field defect) or early extrapyramidal tract signs.

          4. History of cerebrovascular disease and stroke.

          5. Serious lack of folic acid and VitB12, syphilis antibody positive or thyroid
             dysfunction.

          6. Mechanical intestinal obstruction patient ,Resting pulse less than 60,Severe liver or
             renal disease.

          7. Patients with mechanical intestinal obstruction.

          8. History of bone marrow transplantation.Mental illness, such as severe depression.

          9. Cognitive damage caused by alcohol or drug abuse. Disable to correctly evaluate the
             cognitive function.

         10. Critical condition, disable to make the exact evaluation of the efficacy and safety of
             new drug.

         11. Use of any agent for the treatment of dementia within 4 weeks of randomization.

         12. Be sensitive to ACHEI.

         13. Be sensitive to two or more foods/drugs.

         14. Use of another investigational agent within one months of screening.
Clinical trial NCT01206101 (phase 2, status: terminated)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the decision to close the nn2211-3619 trial was based on the very low recruitment rate as well
    as challenges relating to trial execution and study completion.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 5 years

          -  Candidate for islet cell transplantation based upon local accepted practice and
             guidelines

          -  Reduced awareness of hypoglycaemia

        Exclusion Criteria:

          -  Treatment with any anti-diabetic medication other than insulin including insulin pump
             within 4 weeks of trial start

          -  Any previous organ transplantation

          -  A history of acute idiopathic or chronic pancreatitis

          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
             medullary thyroid carcinoma (FMTC)
Clinical trial NCT00503386 (phase 2, status: completed)
Conditions: nausea, vomiting, chemotherapy
ICD codes: R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, D61.810, Z51.11, D64.81, D70.1, Z92.21, P04.11, T80.810S
Drugs: palonosetron, granisetron
SMILES: [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age ≥ 18 yrs and <70 yrs with histologically or cytologically
             confirmed

          -  Malignant disease

          -  Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60

          -  Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60
             ~ 80 mg/m2 on study Day 1

          -  Use of reliable contraceptive measures (for females of childbearing potential) and
             negative pregnancy test at baseline visit

          -  Patients with hepatic, renal, or cardiovascular impairment eligible at the
             investigator's discretion

          -  Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible at
             the investigator's discretion

          -  Predicted life expectancy of ≥ 3 months

          -  Provision of written informed consent.

        Exclusion Criteria:

          -  Inability to understand or cooperate with study procedures

          -  Receipt of investigational drugs ≤ 30 days before study entry

          -  Receipt of other investigational drugs during the course of this study

          -  Seizure disorder or any condition requiring anticonvulsants, sedatives

          -  CNS malignancy or metastasis

          -  Ongoing emesis due to obstruction of digestive tract

          -  Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy

          -  Moderate or severe nausea and vomiting after any previous chemotherapy

          -  Scheduled receipt of any chemotherapeutic agent with an emetogenicity level >3 during
             study Days 2-5

          -  Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 2-5

          -  Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of
             study initiation and throughout day 5

          -  Contraindications to 5-HT3 receptor antagonists

          -  Contraindications to chemotherapy
Clinical trial NCT00351195 (phase 2, status: terminated)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: etoposide, oxaliplatin, capecitabine
SMILES: OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    did not meet the criteria for continuation to second stage
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically verified intra- or extrahepatic inoperable hepatocellular carcinoma or
             hyperdense liver lesion at computed tomography and concurrent elevated
             alpha-feto-protein > 400 ng/ml

          -  PS 0-2

          -  Age 18-75

          -  Life expectancy > 12 weeks

          -  Normal bone marrow function (neutrophiles > 1,5 x 109/l and platelets > 100 x 109/l)

          -  Bilirubin < 2 x UNL

          -  Transaminases < 3 x UNL

          -  Normal renal function, Cr-EDTA clearance > 50 ml/min

          -  No chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion

          -  No uncontrolled, severe concurrent medical disease

          -  Fertile women must have a negative pregnancy test

          -  Fertile women must use adequate contraceptives during and 3 months after trial
             exposure

          -  Signed informed consent

        Exclusion Criteria:

          -  Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion

          -  Experimental therapy < 8 weeks prior to inclusion

          -  Known DPD-deficiency

          -  Known neuropathy

          -  Uncontrolled, severe concurrent medical disease

          -  Prior malignancy during the last 5 years, except for non-melanoma skin cancer and
             carcinoma in situ cervix uteri.
Clinical trial NCT01343745 (phase 2, status: completed)
Conditions: mild persistent asthma
ICD codes: J45.30, J45.31, J45.32
Drugs: bdp/formoterol, bdp/formoterol, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female patients 18-50 years of age, who have signed an informed consent form.

          2. Clinical evidence of asthma

          3. Steroid naïve asthmatic patients

          4. FEV1 at Screening Visit is >70 % of the predicted value and at least 2.0 L.

          5. Body Mass Index between 18 and 35.

          6. Sensitivity to AMP at Screening Visit.

          7. FENO levels >25 ppb at the Screening Visit

        Exclusion Criteria:

          1. Having received an investigational product within 2 months of Screening Visit.

          2. Inability to comply with study procedures or with study treatment intake.

          3. Any significant lung disease which is considered by the investigator to be clinically
             significant.

          4. Patients who suffer from Chronic Obstructive Pulmonary Disease (COPD)

          5. Previous or current smokers who have a smoking history greater than 5 pack years.

          6. Patients with any uncontrolled disease that might, in the judgment of the
             investigator, place the patients at undue risk or potentially compromise the results
             or interpretation of the study.

          7. Patients with QTc >450msec at the Screening Visit.

          8. Patients with serum potassium <3.5 mEq/L or >6 mEq/L.

          9. Intolerance/hypersensitivity or any contra-indication to treatment with beta2-agonists
             and/or inhaled corticosteroids.

         10. Patients who have a history of alcohol or substance abuse that in the opinion of the
             Investigator may be of clinical significance.

         11. Patients who have undergone major surgery in the previous 3 months.

         12. Patients who have had an exacerbation of asthma, requiring treatment with oral
             steroids during the last month prior to Screening Visit.

         13. Patients treated with slow-release corticosteroids 2 months prior to Screening Visit.

         14. Patients currently treated with anti-IgE Antibodies.

         15. Patients who have had a respiratory tract infection within 4-weeks prior to Screening
             Visit.

         16. Females not willing to use effective contraceptive measures such as oral contraceptive
             or intra-uterine device (IUD).

         17. Females who are pregnant, lactating or planning to become pregnant
Clinical trial NCT00504270 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo, rg3421 120mg, rg3421 20mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-70 years of age;

          -  medically stable, moderate to severe chronic plaque psoriasis.

        Exclusion Criteria:

          -  any skin condition which may interfere with evaluation of the effect of study
             medication on plaque lesions;

          -  confounding or concomitant condition or treatment.
Clinical trial NCT00474916 (phase 2, status: completed)
Conditions: neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: krn5500, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Diagnosis of advanced or recurrent cancer

          -  No options for curative chemotherapy, but palliative chemotherapy allowed under
             certain conditions

          -  Refractory neuropathic pain rated 4 or greater on 0-10 scale and failure to respond to
             2 commonly used treatments

          -  If taking opioids for pain, stable regimen over past week before enrolling

          -  Karnofsky performance status of 40 or more

          -  Females must be sterile or post-menopausal

        Exclusion Criteria:

          -  Radiation to site of neuropathic pain for past 4 weeks

          -  Major surgery within past 2 weeks

          -  Liver function and other key labs outside normal parameters

          -  ECG showing significant abnormality

          -  Myocardial Infarction (heart attack) within past 6 months

          -  History of interstitial lung disease

          -  History of severe allergic reaction to drugs containing polysorbate 80

          -  Other investigational drug within 2 weeks or 5 half-lives (whichever is longer
Clinical trial NCT00563706 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: vabicaserin, risperidone
SMILES: C1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy, men and women, aged 18 to 65.

          -  Hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of
             schizophrenia established greater than 1 year.

          -  Ability to remain hospitalized for the duration of the screening period and for 4
             weeks of double-blind treatment.

        Exclusion Criteria:

          -  Current Axis I primary psychiatric diagnosis other than schizophrenia (DSM-IV-TR
             criteria).

          -  Current diagnosis or history of substance abuse or dependence (DSM-IV-TR criteria),
             including alcohol (except for nicotine), within 3 months before baseline (day -1).

          -  Subjects taking high or chronic doses of benzodiazepine at the screening evaluation
             who, in the investigator's judgment, would be likely to have severe withdrawal
             symptoms upon discontinuation.
Clinical trial NCT00325351 (phase 2, status: completed)
Conditions: ovarian neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sagopilone (zk 219477) + carboplatin
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Eligibility criteria:

        Inclusion Criteria:- Must have evidence of ovarian cancer measurable by computed tomography
        (CT) scan or by CA125 blood levels- No radiation therapy in last 4 weeks- No chemotherapy
        in last 24 weeks - No immunotherapy in last 4 weeks- Good response after previous treatment
        with carboplatin or cisplatin and then the ovarian cancer got worse again after at least 6
        months- Additional criteria determined at screening visit Exclusion Criteria:- Having had
        more than one treatment regimen with carboplatin or cisplatin- Prior treatment with other
        epothilones (e.g. ixabepilone)- Use of any investigational drug in the last 4 weeks-
        Previous radiation to the whole pelvis- Symptomatic brain tumors requiring radiation to the
        brain - Active infection- Pregnant or breast feeding- Additional criteria determined at
        screening visit
Clinical trial NCT00712062 (phase 2, status: withdrawn)
Conditions: primary central nervous system lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological confirmation of Primary Central Nervous System Lymphoma

          -  Male or female > 18 years of age or older

          -  Negative pregnancy test (if of childbearing potential)

          -  Any number of previous recurrences will be allowed

          -  Karnofsky Performance Status > 60

          -  Hematocrit > 30,000

          -  Platelet > 100,000

          -  Absolute Neutrophil Count > 1,500

          -  Bilirubin < 1.5 x upper limits of normal

          -  Transaminases (ALT and AST) < 1.5 x upper limits of normal

          -  Creatinine < 1.5 x upper limits of normal

          -  Creatinine Clearance > 45 mL/min

          -  Adequate medical health to participate in this study

          -  Adequate documentation of menopause (natural/surgical) or patient commitment to
             routine use of reliable birth control (barrier/hormonal)

          -  Ability to read and understand the patient informed consent form

          -  Ability and willingness to follow all requirements of the study including following
             all directions, taking medication as prescribed, and completion of all diaries and
             forms

        Exclusion Criteria:

          -  Karnofsky Performance Status < 60

          -  Hematocrit < 30,000

          -  Platelet < 100,000

          -  Absolute Neutrophil Count < 1,500

          -  Bilirubin >1.5 x upper limits of normal

          -  Transaminases (ALT & AST) > 1.5 x upper limits of normal

          -  Creatinine > 1.5 x upper limits of normal

          -  Creatinine Clearance < 45 mL/min

          -  Inability to undergo gadolinium-contrasted MRIs, including severe claustrophobia or
             insufficient allergy prophylaxis
Clinical trial NCT00323817 (phase 2, status: completed)
Conditions: functional dyspepsia
ICD codes: K30
Drugs: z-338
SMILES: COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects presenting diagnosis of FD as defined by the Rome II

          -  Subjects presenting postprandial fullness and/or Early satiety should be the most
             bothersome symptom

        Exclusion Criteria:

        -
Clinical trial NCT00600067 (phase 2, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: phentermine/topiramate, placebo
SMILES: CC(C)(N)CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have completed the qualifying OB-202 trial

          -  If females of child-bearing potential, subjects must be using adequate contraception

          -  Provide written informed consent

          -  Be willing and able to comply with scheduled study visits, treatment plan, lab tests
             and other study procedures

        Exclusion Criteria:

          -  Subjects who have developed one or more morbidities during the OB-202 trial that would
             pose a safety concern